Syntara Limited to Present New Data on Myelofibrosis Treatment at EHA2025

The latest update is out from Pharmaxis Ltd ( (AU:SNT) ).

Syntara Limited announced an investor webinar to discuss new interim data from its Phase 2 study of SNT-5505 in myelofibrosis. The data will be presented at the European Hematology Association 2025 Congress. This announcement highlights Syntara’s ongoing efforts to advance SNT-5505, which has received Fast Track Designation and FDA Orphan Drug Designation. The development of SNT-5505, alongside other drug candidates, positions Syntara as a significant player in the treatment of blood cancers and fibrotic diseases, potentially impacting stakeholders by advancing treatment options in these areas.

The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.25 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.

More about Pharmaxis Ltd

Syntara Limited is a clinical-stage drug development company specializing in targeting extracellular matrix dysfunction. With expertise in amine oxidase chemistry, Syntara focuses on developing novel medicines for blood cancers and conditions related to inflammation and fibrosis. The company is advancing its lead candidate, SNT-5505, for treating myelofibrosis, a bone marrow cancer, and is also working on other drug candidates for fibrotic and inflammatory diseases. Syntara is listed on the Australian Securities Exchange and is based in Sydney, Australia.

Average Trading Volume: 8,136,081

Technical Sentiment Signal: Buy

Current Market Cap: A$112.1M

For detailed information about SNT stock, go to TipRanks’ Stock Analysis page.